Scorpius Holdings, Inc.: Nasdaq/NYSE listing notice — Scorpius Holdings receives NYSE delisting notice for late 10-K and low stock price; trading suspended

Scorpius Holdings, Inc.

April 16: NYSE notice for failure to timely file 2024 10-K (due April 15, 2025); 6-month cure period begins.
April 21: NYSE suspends trading and commences delisting proceedings due to low selling price under Section 1003(f)(v).
Company intends to request a review of delisting determination, but appeal outcome is uncertain.
If cure periods expire or appeal fails, suspension and delisting will proceed; no additional cure period guaranteed.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Scorpius Holdings, Inc. received a nyse_american noncompliance notice notice regarding late filing (rules 1007).

Exchange: nyse american
Notice: noncompliance notice
Deficiency: late filing
Rules: 1007

Exact text from the filing

April 16, 2025 Notification On April 16, 2025, Scorpius Holdings, Inc. (the “Company”) received a notice (the “Notice”) from the NYSE Regulation (the "Notice") stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (the "Exchange") under the timely filing criteria included in Section 1007 of the NYSE American Company Guide (the "Company Guide") because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2024 (the "Delinquent Report"), which was due to be filed with the Securities and Exchange Comm

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001079973-25-000687

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.